Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
India has the second-largest number of adults with diabetes globally, after China
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Go-ahead for pivotal clinical trial which is expected to commence by March
Subscribe To Our Newsletter & Stay Updated
